All In Biotech

Drug Trial Radar · NCT04647487

A Study of LY3484356 in Women With Breast Cancer Before Having Surgery

EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Last checked: Nov 20, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

87

Actual

Start

Apr 21, 2021

Primary completion

Nov 11, 2022

Study completion Nov 11, 2022

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Dec 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery. Participation in this study could last up to 2.5 months.

Conditions

  • Breast Cancer

Interventions

  • LY3484356Drug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Estrogen Receptor (ER) ExpressionTime frame: Baseline, Day 15

Locations

19 sites in 6 countries. Site status is shown where the registry gives one.

  • Winship Cancer Center Emory University

    Atlanta, Georgia

  • Northwestern Memorial Hosptial

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Sarah Cannon Research Institute SCRI

    Nashville, Tennessee

  • Baylor College of Medicine

    Houston, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Vermont Medical Center

    Burlington, Vermont

  • Institut Jules Bordet

    Brussel - Capital, Belgium

  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

    Leuven, Belgium

  • Hôpital René Huguenin

    Saint-Cloud, Hauts-de-Seine, France

  • Klinikum der Universitaet Muenchen

    München, Germany

  • Universitätsklinikum Erlangen

    Erlangen, Bavaria, Germany

  • Helios Kliniken Schwerin

    Schwerin, Mecklenburg-Vorpommern, Germany

  • Hospital Clinic I Provincial

    Barcelona, Spain

  • Hospital General Universitario Gregorio Marañon

    Madrid, Spain

  • Hospital Madrid Norte Sanchinarro

    Madrid, Spain

  • The Royal Cornwall Hospital

    Truro, Cornwall, United Kingdom

  • Barts Cancer Institute

    London, London City, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.